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Indrani Mahapatra,a J. Clark,a Peter J. Dobson,b Richard Owenc and Jamie R. Lead*ad
The application of nanotechnology and nanoscience for medical purposes is anticipated to make signiﬁcant
contributions to enhance human health in the coming decades. However, the possible future mass
production and use of these medical innovations exhibiting novel and multifunctional properties will very
likely lead to discharges into the environment giving rise to potentially new environmental hazards and risks.
To date, the sources, the release form and environmental fate and exposure of nano-enabled medical
products have not been investigated and little or no data exists, although there are a small number of
currently approved medical applications and a number in clinical trials. This paper discusses the current
technological and regulatory landscape and potential hazards and risks to the environment of nano-enabled
medical products, data gaps and gives tentative suggestions relating to possible environmental hotspots.Environmental impact
The application of nanotechnology in healthcare is emerging as an important strategic area of research and it is likely to make signicant contributions to
improving healthcare in coming decades. However, the likely emergence of large scale nanomedicine production is likely to lead to signicant environmental
exposure of bioactive and potentially toxic nanomaterials. The bioactive nature of these materials might lead to enhanced risk e.g. in enhanced ‘Trojan Horse’
type mechanisms in drug delivery vehicles. By controlling exposure and/or by designing drugs eﬀectively with environmental concerns in mind will maximize
benet and minimize risk. In order to prompt a discussion of this emerging area, this review presents the current status of nanomedicine developments, brings
together the knowledge from the eld of environment impact research of pharmaceuticals and nanomaterials and the existing regulatory guidelines to identify
knowledge gaps and uncertainties which need to be addressed to ensure a safe, sustainable and eﬀective technology is produced and used.Introduction
Nanotechnology is a large, convergent, multidisciplinary enabling
eld that is rapidly growing.1,2 Size dependent properties due to
spatial connement along with their high specic surface area
and surface energies, give nanomaterials (NMs) unique, size
dependent and tuneable electronic and optical behaviour. Such
properties can be exploited in a range of applications including in
nanomedicine,† which also utilise other nanoscale properties
such as their ability to interact with the cellular machinery and
potential for targeted cellular and sub-cellular compartmentali-
zation.3,4 Applications of nanotechnology in healthcare can be as
platforms for drug delivery, for enhancing outcomes of various
treatment types such as photothermal therapy, thermal ablation
and hyperthermia treatments, in vitro detection of biomarkers,ntal Sciences, University of Birmingham,
bham.ac.uk
, Begbroke, OX5 1PF, UK
r, EX4 4PU, UK
ences, Arnold School of Public Health,
uth Carolina 29208, USA
d medical products and nano-enabled
rchangeably in the text.
Chemistry 2013imaging, and as combined drug and diagnostics devices –
“theranostics” (for more details, see ref. 5–8).
Applications of nanotechnology can increase the eﬃcacy of
therapeutics by providing solutions to the traditional problems
associated with pharmaceutical solubility,9 limiting systemic
toxicities,‡10 bioavailability,12 immunocompatibility13 and
cellular uptake.14 Nanotechnology based therapeutics can be
produced either through top down processes such as milling,
high pressurised homogenisation, etching, lithography and
other methods, or through bottom up processes, such as
chemical synthesis both for inorganic NMs or complex poly-
meric designs to act as therapeutic agents or carriers of thera-
peutic agents.§ These nanocarriers{ can be used to encapsulate
and/or conjugate therapeutic agents like pDNA, siRNA and
traditional chemotherapeutics (e.g., paclitaxel, doxorubicin,‡ Systemic toxicity refers to adverse eﬀects on any organ system following
absorption and distribution of a chemical throughout the body (see ref. 11).
§ Therapeutic agents can be small molecule drugs, biotechnology derived
products e.g., cell, oligonucleotides, monoclonal antibodies, polymers, and
vaccines. The terms therapeutics agents, pharmaceuticals and drugs has been
used interchangeably in the text.
{ Sometimes called nanovectors or drug delivery systems/vehicles or
nanoconstructs.
Environ. Sci.: Processes Impacts, 2013, 15, 123–144 | 123
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View Article Onlineirinotecan)9,15–17 which have had limited applications in clinical
settings due to biological degradation, high systemic toxicities
or other factors. Additionally, functionalization of the surface of
these NMs using aptamers, antibodies, and cell receptor rec-
ognising proteins helps to achieve targeted drug delivery.
Nano-enabled in vitro diagnostic devices can help in the
detection and early diagnosis of diseases like cancer (e.g., see a
recent review, ref. 18) with increased sensitivity19 and in a non-
invasive manner.20 In addition to in vitro diagnostics,Indrani Mahapatra has worked
in the areas of health risk
assessment due to industrial and
indoor air pollution, corporate
sustainability reporting and
assurance, corporate sustainable
sourcing strategies, hazardous
waste issues and management,
and implementation of renew-
able energy projects at commu-
nity level. She has a Master's in
Environment Management and is
currently pursuing Ph.D. at
University of Birmingham, U.K.
J. Clark is Senior Lecturer in
Geography at University of Bir-
mingham. His research focuses
on political geographies of
Europe, the political governance
of natural resources, and the
interrelations between political
geography and political science.
He has published widely on
political geography and environ-
mental governance and has
research monographs published
by Oxford University Press and
Routledge-Cavendish.
Peter J. Dobson currently holds
the position of Academic Director
at Begbroke Science Park,
University of Oxford and is the
Chief Strategic Advisor on Nano-
technology to the Research
Councils in the UK. His research
interests primarily lies in the
areas of most aspects of nano-
technology with focus on appli-
cations to medicine. He founded
two spin-oﬀ two companies,
Oxonica plc and Oxford Biosen-
sors Ltd., in the decade of 1990–2000. He was named the Innovator
of the Year in 2005 by the Small Times Magazine. He advises
several corporate and government organisations on nanotechnology
and knowledge transfer.
124 | Environ. Sci.: Processes Impacts, 2013, 15, 123–144nanotechnology is being used to developnewMRI contrast agents
for in vivo diagnostics for contrast enhancement. For instance, a
ten-fold increase in MRI contrast in comparison to clinical Gd(III)
contrast agents e.g. Gd–DTPA and Gd–DOTA was observed by
using nanodiamond conjugated to Gadolinium(III) [Gd(III)–ND].21
Due to these advantages, research anddevelopment investment of
nanotechnology andnanomedicinehas increased rapidly over the
last 10 years, and it is likely that production and use of nano-
enabled medical applications will rise in the coming years.
A recent, detailed study has estimated that there are currently
247 nanomedical products that have been approved and are in
the market or are in early or late stages of clinical trials, with
many more in development.22 A market research rm, BCC
research, has estimated that the nanomedical global market
value increased fromUSD53billion in2009 toUSD72.8billion in
2011. Additionally, the rm has projected a compound annual
growth rate in the globalmarket for nanomedicines to be 12.5%,
between the years 2011 and 2016, with largest growth in the
therapeutic area of oncology anddisorders of the central nervous
system (CNS).23,24 The applications currently in clinical devel-
opment belong to the categories of liposomal formulations,
polymer–protein and polymer–drug conjugates, micelles, anti-
body–drug conjugates, dendrimers, metal andmetal oxide NMs.
Please see Table 1 exemplifying each of these categories.Richard Owen holds the Chair in
Responsible Innovation at the
University of Exeter Business
School, where he is Director of
Postgraduate Research. Richard's
research involves understanding
the responsible emergence of
innovation and new technologies
in democratic society, with a
particular emphasis on gover-
nance. Richard is a member of
EPSRC's Strategic Advisory
Network where he advises on
societal and ethical issues.
Jamie Lead is the Chair in Envi-
ronmental Nanoscience and Risk
and Director of the SmartState
Center for Environmental Nano-
science and Risk for at University
of South Carolina, U.S.A and
adjunct Professor of Environ-
mental Nanoscience and Founder
and Co-Director of the Facility for
Environmental Nanoscience and
Characterisation at the Univer-
sity of Birmingham, UK. His
research interests cover nano-
scale phenomena in environmental systems, including natural and
manufactured materials, their interactions, chemistry, fate and
eﬀects, risk and regulation.
This journal is ª The Royal Society of Chemistry 2013
Table 1 Examples of nano-enabled medical applications (in market and in development)
Details Nanocomponent (size) Drug or device Reference
Diagnosis of lung cancer, breast, colon cancer, gastric
lesions, etc. and multiple sclerosis from biomarkers in
exhaled breath
Gold NPs (5 nm), SWCNT Device 20 and 52–56
Alkylated polyethylenimine (PEI) nanoparticles (NPs)
incorporated in composite resin dental restorative
materials to reduce bacterial infections and dental caries
PEI NPs Device 57
Obturators lined with silicon incorporated with quaternary
ammonium polyethylenimine (PEI) NPs for managing post
surgery infection in head and neck cancer
PEI NPs Device 58
Liposomal formulation of two anti-leishmaniasis drugs for
treatment of leishmaniasis
Liposome Drug 59
Liposome formulation of combination anticancer drugs: Liposome Drug 60
 cytarabine and daunorubicin for acute myeloid leukemia
 irinotecan and oxuridine for colorectal cancer
Chemotherapeutic drug (paclitaxel) associated albumin
nanoparticles used as last line treatment for metastatic
breast cancer
Albumin NPs (130 nm) Drug 61
Chemotherapeutic drug doxorubicin associated with
polyethylene glycol (PEG) liposomes
PEGylated liposomes Drug 62
 PEGylated interferons + drug for treatment of hepatitis C PEGylated proteins Drug Summarised
in ref. 5, see
also ref. 63
methoxy PEGylated erythropoietin receptor activators for
anaemic patients with chronic kidney disease or myeloma
monoclonal antibody directed against TNF-a with a PEG
tail for treatment of rheumatoid arthritis and Crohn's
disease
Thermosensitive liposome in combination with
doxorubicin and radiofrequency ablation or hyperthermia
or high intensity focussed ultrasound for treatment of
breast cancer, colorectal liver and bone metastases
Thermosensitive liposome Drug 64–66
Chemotherapeutic drug paclitaxel in polymeric micelles
for treatment of breast cancer, lung cancer, advanced
ovarian cancer
PEG and poly(D,L-lactic
acid) polymeric micelle
Drug 41 and 67
Anticancer drugs paclitaxel, cisplatin and oxaliplatin in
polymeric micelles
Polymeric micelle Drug 68
Radioactive Yttrium-90 conjugated with monoclonal
antibody directed against CD40 antigen of B cells for
treatment of relapsed or refractory, low-grade, follicular or
B-cell non Hodgkin's lymphoma (nuclear medicine or
biotech medicine)
— Drug Summarised
in ref. 5
Circulating tumour cells test/assay for diagnosis of
metastatic breast, colorectal or prostate cancer: ferro-
magnetic NPs labelled with monoclonal antibodies
corresponding to specic antigen expressed in cancer cells
Magnetic nanoparticles Device 69
Infectious disease tests, cardiac tests, etc. using gold NPs
functionalised with specic biomolecules like
oligonucleotides, antibodies
Gold NPs (13–20 nm) Device 70
Fih generation PAMAM dendrimers used for
immunoassays as conrmation test for the occurrence of
myocardial ischemia
Dendrimers Device 71 and 72
Mannosylated polyethylenimine (PEI) polymers
containing plasmid DNA as therapeutic vaccine for HIV/
AIDS
PEI polymers Device (the delivery
patch)
17 and 73
A fourth generation L-lysine dendrimer with naphthalene
disulfonic acid surface groups in a gel base for treatment
of bacterial vaginosis, coating of condoms for sexually
transmitted diseases, etc.
Lysine dendrimer Drug 74 and 75
PEGylated colloidal gold bound TNF for treatment of
advanced solid tumors
Gold NPs (27 nm) Drug 76
Gold coated silica nanoparticles for thermal ablation of
refractory head and neck cancer
Au–Si NP (150 nm) Device 77
This journal is ª The Royal Society of Chemistry 2013 Environ. Sci.: Processes Impacts, 2013, 15, 123–144 | 125
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Table 1 (Contd. )
Details Nanocomponent (size) Drug or device Reference
Bio bar code assay: it has a magnetic micro particle plate
functionalised with target specic recognition agents (in
this case monoclonal anti-PSA antibodies) and the second
component is AuNP probes, average 30 nm size, carrying
hundreds of DNA strands and PSA strands leading to
amplication of the signal. Detection of prostate cancer
relapse post-prostatectomy
AuNP probes (average 30
nm)
Device 19
Superparamagnetic iron oxide nanoparticles as contrast
agents for delineating the bowel, glioblastoma
multiforme, lymph nodes in prostate cancer
Iron oxide NPsa Drug 78–80
Iron oxide nanoparticles coated with polyglucose sorbitol
carboxymethyl ether for treatment of iron deciency
anaemia in chronic kidney disease
Iron oxide NPs (30 nm with
coating)
Drug 81 and 82
SPIONs (superparamagnetic iron oxide NPs) for tracking of
inammatory (mononuclear) cells
Iron oxide NPsa Drug 83
SPIONS with aminosilane coating for treatment of
multiforme glioblastoma (an aggressive brain cancer) in
combination with application of external magnetic eld
15 nm iron oxide NPs Device 84
Silver nanoparticles associated with wound dressings Nanocrystalline silver Device 85
Nano silver hand gel Nanosilver Drug 86
Nano silver impregnated activated carbon wound dressing Nanosilver Drug and device
combination
87
Nano silver coated latex central venous catheters to reduce
chances of infections
Nanosilver Device 88
a Though the exact sizes are not known here, superparamagnetic and ultrasuperparamagnetic iron oxide nanoparticles are mainly made of g Fe2O3
and Fe3O4 and have core diameter <25 nm (see ref. 89) and 5–12 nm (cited in ref. 90) respectively. These magnetic particles are coated with silica,
dextran, etc. for specic applications.
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View Article OnlineOnly a few earlier publications to date have discussed
potential issues related to nanotoxicity of nanomedicine and
the majority of these have drawn extensively upon from the
literature relating specically to health impacts of ne partic-
ulates.25–28 Occupational exposure from nanomedical applica-
tions and ways of monitoring was discussed by Murashov.29 To
the best of our knowledge, Baun and Hansen30 were the rst to
publish their perspective specically regarding nanomedicine
and the environment. These early statements of problem
formulation strongly suggest the need for research on ecotox-
icology, environmental exposures and risks. Subsequently, a
handful of empirical studies have been published in this area
(see Table 3). Additionally, the European Medicines Agency in
2010 conducted a workshop on nanomedicines and had a
discussion on specic methodological issues for environmental
risk assessment of nanomedicines.31 However, concrete steps
are yet to be taken in this area. The nascent stage of the nano-
medicine eld, the assumption that more targeted medicines
will reduce dosages, and that safety issues are covered in the
stringent and well controlled development pathway of thera-
peutics are all reasons for this lack of action in this area.
However, assumptions for pharmaceuticals have previously
been made, e.g., that their small amount compared to other
chemicals would not pose any risk and that pharmaceutical
industries follow good manufacturing practices, but the current
environmental research focusing on pharmaceuticals indicates
that problems are arising.32 In addition, a number of other
issues are pertinent: (1) it is appropriate to consider these issues126 | Environ. Sci.: Processes Impacts, 2013, 15, 123–144at an early stage before development is ‘locked’ in by economic
and other factors, (2) targeting will increase solubility and
bioavailability in the environment even though medical dosages
used might be low and (3) stringent regulatory controls are
evident in the human area but less so for environmental expo-
sure and behaviour. Therefore, it is appropriate to critically
review the available information in this area, understand the
knowledge gaps and address this potential issue at an early stage.
In this review, we discuss (i) the existing status of denitions of
nanomedicine and a few relevant examples of nanomedicines
under development, (ii) the current status of knowledge regarding
environmental hazards and risks of conventional pharmaceuti-
cals and nanomaterials with a view to understanding the envi-
ronmental risks of nanomedicines, (iii) existing regulatory
framework for pharmaceuticals for human use and medical
devices and its coverage in the context of nanomedical applica-
tions and (iv) uncertainties and knowledge gaps.
This paper focuses on nanomedical applications which are
marketed or are in advanced stages of clinical development. The
nanomedical applications that ndmention in the text belong to
the category of therapeutics and diagnostics. Developments and
clinical applications in regenerative nanomedicine are excluded
in this review. There are a large number of proof-of-concept works
related to nanocarriers based on fullerenes, carbon nanotubes,
nanodiamonds, graphene, etc. which have immense potential for
a myriad of applications in drug delivery. However, to the best
of the knowledge of the authors, disease treatment strategies
which have shown potential either in vitro or in proof-of-conceptThis journal is ª The Royal Society of Chemistry 2013
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View Article Onlineexperiments using these materials are yet to move beyond pre-
clinical stage, therefore, this paper doesn't focus on these mate-
rials. A lot of ecotoxicity research has been conducted on
quantum dots (CdTe/CdSe as core), but these ecotoxicity studies
are not being reviewed here because the use of quantum dots is
not directly related to clinical applications. Of course, quantum
dots are used in life sciences for cell imaging, tracking and
elucidating biochemical mechanisms, hence they are important
for medical research and innovation, but they are beyond the
scope of this review. There is only one in vitro diagnostic device in
the clinical trial phase which possibly uses SWCNT (single walled
carbon nanotube), therefore, this paper also doesn't focus on the
ecotoxicity research conducted on carbon nanotubes. The
governance and regulatory framework explained in the text is EU
centric and the paper refrains from touching upon other regu-
latory guidelines existing beyond the EU, unless exceptionally
necessary to explain a particular section.Nanotechnology in healthcare applications
The aim of nanomedicine is the comprehensive monitoring,
repair and improvement of all human biological systems,
working from the molecular level using engineered devices and
nanostructures to achieve medical benet. The concept
includes nanoscale active components or objects ranging in size
from 1 nm to 100s of nm.33 The European Commission's
recommendation on the denition of nanomaterial creates a
special case for pharmaceuticals and medical devices. The
recommendation mentions that the proposed size cut-oﬀ value
of 1 to 100 nm, with more than 50% of particles by number in
this range, should not prejudice pharmaceutical and the
medical devices sectors.34 Thus, though mainstream nano-
technology explores particles between 1 and 100 nm in diam-
eter, for nanomedicine, the size of the nanomaterials might in
totality exceed 100 nm. The US FDA is yet to dene nano-
material or nanomedicine. Therefore, a widely accepted and
clear denition is essential for appropriate regulation of nano-
medicine but is not in place as yet due to novelty and multi-
disciplinarity of the eld and broad range of applications that
can be developed in the context of other convergent technolo-
gies. Nevertheless, rapid progress towards a denition is
essential for regulatory purposes.
Nanomaterials are broadly classied into two categories based
on the type of interactions exploited for designing nanomedicine.
These two categories are ‘hard’ and ‘so’. Hard nanomaterials are
metal and metal oxide nanoparticles, fullerenes, etc. formed via
ionic or covalent bonds, whereas ‘so’ nanocarriers use weak
interactions.35 The key types of hard nanomaterials currently
being investigated for clinical applications and in the market are
AgNPs, AuNPs and FexOy NPs. AgNPs has an antimicrobial eﬀect
and nds it uses in bandages for burn injuries, catheters and
others. The potential for AuNPs in biomedical applications is due
to its surface chemistry which makes it amenable to coating and
functionalising with various targeting ligands, relative biocom-
patibility and photo-optical properties.36 FexOy NPs are used
because at nanoscale iron oxide exhibits super-paramagnetism
and can be used as contrast agents as well as for hyperthermiaThis journal is ª The Royal Society of Chemistry 2013treatments for cancer.37,38 Formulating metal and metal oxide
NMs of diﬀerent sizes and surface coating can help develop
various biomedical applications.
The key types of ‘so’ nanocarriers in the market or in
advanced stages of development are:
 Liposomes are spherical vesicles composed of amphiphilic
phospholipids and cholesterol, which self-assemble into bila-
yers to encapsulate an aqueous interior. They are one of the
oldest and widely recognised nanocarriers and they can serve as
a platform for delivery of both hydrophilic and hydrophobic
therapeutic agents (see ref. 39 and references therein). Lipo-
somes vary greatly in size from 25 nm to 5000 nm (ref. 40) and
can be classied in terms of composition and mechanism of
intracellular delivery into ve types: conventional liposomes,
pH-sensitive liposomes, cationic liposomes, immunolipo-
somes, and long-circulating or PEGylated liposomes.41
 Dendrimers are synthetic polymers (e.g. polyamidoamine,
polypropylene imine) in which the atoms are arranged in many
branches and sub-branches radiating out from a central core
and sizes can be in the nm to mm range. Dendrimers can be
categorized based on the number of the branches they possess
which are called generations (G1, G2, G3, etc.). Dendrimers are
being identied as ideal nanoscale drug delivery systems due
their capacity to carry multiple modalities (therapeutic,
imaging, and targeting). A plethora of diﬀerent dendrimer
compositions and chemical surface modications can be
synthesized and dendrimers can themselves act as therapeutic
agents (for further details, see ref. 42–44).
 Micelles are nanosized, spherical colloidal particles with a
hydrophobic interior (core) and a hydrophilic exterior (shell).
Drugs or contrast agents may be entrapped within the hydro-
phobic core or linked covalently to the surface of micelles (for
examples, see ref. 45).
Nanocarrier design requirements: The key principles govern-
ing rational design considerations of nanocarriers are:46,47
 physiologically stable nanocarriers capable of evading the
reticuloendothelial system/mononuclear phagocytic system
 amenability to surface functionalisation with targeting
moieties such as antibodies and cell penetrating peptides
 ability to cross the biological barriers of the body
 availability of a clearance mechanism that does not harm
other organs
 ability to release the drug payload at the required site
(delivery can also be designed so that it is modulated by pH or
redox changes, enzymatic cleavage of bonds or activated by
external stimulus such as electro-magnetic elds)
 biodegradability and biocompatibility, i.e., low or no
immunotoxic, genotoxic, mutagenic, reproductive and devel-
opmental toxic eﬀect for human beings.
These design features of nanocarriers will have the potential
to increase therapeutic eﬃcacy by protecting the therapeutic
agents from being physically, chemically, biologically
‘degraded’ before they reach the disease target site and being
released at this site. For instance, siRNA has been encapsulated
in a 70 nm cyclodextrin based polymer, conjugated with a
protein as a targeting ligand and polyethylene glycol (PEG)
polymer to promote stability.15 Design strategies can also helpEnviron. Sci.: Processes Impacts, 2013, 15, 123–144 | 127
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View Article Onlinein escaping the biological barriers, have better control over drug
release prole, increase absorption in tumours tissues, prevent
therapeutic agents from interacting with normal cells and
hence less systemic toxicities.48–50 If these carriers are designed
with the aim to treat CNS disorders, these features can also help
the small drug molecules to cross the blood brain barrier and
hence improve the therapeutic outcomes.
However, the design features necessary to make eﬃcacious
therapeutics might prove to have deleterious impacts on envi-
ronmental biota and ecological health, when these medicines
nd their way into the environment. Furthermore, not all
design features listed above can be met for development of a
particular therapeutic. For example, PEG coated therapeutics,
so-called ‘stealth’ nanoparticles are in advanced stages of clin-
ical trials, however it has been found that PEG is not easily
biodegradable in the human body (mentioned in ref. 5 and 51).
At the same time, more targeted and in some cases reduced
dosages might decrease the future environmental burden of
conventional pharmaceuticals.The context of existing pharmaceuticals and
environmental risks
The primary focus of drug delivery research in nanomedicine has
been to design delivery agents that would have the ability to cross
the various biological barriers in the body and deliver therapeutic
agents to the target site with the aim to increase therapeutic
eﬃcacy. The therapeutic agent might be conventional small
molecule drugs which have found limited use in the clinic due to
systemic toxic eﬀects or poor solubility. This necessitates the
review of the existing scientic literature on conventional phar-
maceuticals in the environment. Concerns due to eﬀects of
pharmaceutical products (PPs)k in the environment have been
expressed91,92 and this is now an active area of research. PPs from
various therapeutic classes have been detected in the range of ng
L1 (and ng g1) to low mg L1 (mg kg1) in diﬀerent environment
compartments, – sewage eﬄuents,93 surface waters,94,95 receiving
coastal waters,96 estuaries,97 sediments and soils,98 landll leach-
ates,99 and to a lower concentration and frequency in groundwater
and drinking water sources.100,101 In many cases (see Table 2)
concentrations of PPs has shown to exceed the current PECsw**
threshold limit value of 0.01 mg L1 suggested by the EMA.102 PPs
have also been found in aquatic biota.32,103,104 The widely detected
pharmaceutical products in the environment belong to the ther-
apeutic class of antibiotics, non-steroidal anti-inammatory
drugs, blood lipid lowering agents, sex hormones, central nervous
system (CNS) disorder drugs and b-blockers (reviewed and
summarized in ref. 105). A few examples of the occurrence of
pharmaceuticals and theirmetabolites in diﬀerent environmental
compartments are presented in Table 2. Spatial, temporal and
geographic variations (e.g., ref. 93, 106 and 107) have been shownk The term ‘pharmaceuticals products’ (PPs) used in the text in this section
includes prodrugs, pharmaceuticals, metabolites and transformation products.
Unless otherwise mentioned, pharmaceuticals mean pharmaceuticals for
human use.
** PECsw is Predicted Environmental Concentration in surface waters.
128 | Environ. Sci.: Processes Impacts, 2013, 15, 123–144to occur in the concentrations and type of pharmaceutical prod-
ucts. Fluctuations in the concentrations of pharmaceutical
products have also been shown in eﬄuents and receiving water
bodies during special episodes, e.g., of disease outbreaks.108,109 In
addition to monitoring campaigns, models such as SimpleTreat,
LowFlow 2000-WQX, PhATE have been used to predict environ-
mental concentrations in various compartments.110,111
Pharmaceuticals are metabolised and excreted out of the
body either unchanged or in conjugated form (e.g. glucuronide,
sulphates, glycinate conjugates) and hence the main sources for
human pharmaceuticals and their metabolites in the environ-
ment have been identied as eﬄuents of waste water treatment
plants (WWTPs) from communities112 hospitals113 and phar-
maceutical manufacturing facilities.32 Approximately, 28% of
the world's population in 2008 was not connected to sewage
systems114 and ca. 9% of the wastewater in EU countries is not
treated or the waste water treatment systems do not have
secondary treatment steps,115 sewage systems are leaky116 or
contamination of storm water from waste water exists117 thereby
giving rise to the possibility of further environmental contam-
ination. It has been established that the fate, removal and
partitioning of these compounds are dependent on the design
of the WWTP,118 e.g., ibuprofen's removal eﬃciency was below
25% for a WWTP having primary treatment process compared
with a removal eﬃciency of 90% in a WWTP having secondary
treatment.96 Furthermore, a few drugs have been shown to have
negative removal percentages in the WWTPs, and it has been
suggested that these negative removal percentages might be
due to analytical instrumental errors, sampling variations, etc.,
but, it also gives credence to the hypothesis that the conjugated
metabolites may undergo bio-transformation in the environ-
ment to form the parent drug (removal eﬃciencies in WWTPs
has been reviewed in ref. 119). PPs can also undergo abiotic
transformations in the environmental matrices including
photo-transformation and hydrolysis and can be deactivated to
ecologically benign molecules or form harmful transformation
products. For instance, the photo-transformation of diazepam
and its metabolites was recently studied120 and the investigators
concluded that diazepam (a widely prescribed antidepressant)
would be transformed under conditions present in the envi-
ronment. However, the photoproducts that were identied had
chemical structures similar to identied endocrine disruptors
(photolytic and oxidative transformation of drugs has been
reviewed in ref. 121).
PPs like ibuprofen, acetaminophen, ciprooxacin, ketopro-
fen, etc. have high removal eﬃciencies in WWTPs which have
secondary treatment steps. However, studies have also estab-
lished that certain PPs (e.g. fenobrate and anthracyclines from
the blood lipid regulator and anticancer therapeutic class
respectively) sometimes get removed from the aqueous phase
and get adsorbed to the sludge/solids.122,123 This may be due to
hydrophobicity, binding interactions with particles in soils, etc.
and thereby contributing to a new exposure pathway when this
nutrient rich sludge is used for agricultural purposes.
Pharmaceuticals are designed to aﬀect biological receptors
and hence it should not come as a surprise that they have stim-
ulatory or inhibitory or dual eﬀects on non-target organisms uponThis journal is ª The Royal Society of Chemistry 2013
Table 2 Measured environmental concentrations of select pharmaceuticalsa
Category Pharmaceutical product Concentration Environmental compartment Region Reference
Analgesics/NSAIDs Acetaminophen 1.89 mg L1 (max. conc.) Groundwater U.S.A. (California) 100
0.08–13.8 mg L1 Treated eﬄuents (5 STPs) Spain 93
1.4–5.9 mg L1 Untreated eﬄuent from
2 hospitals
Italy 113
0.012–0.058 mg L1 STP eﬄuent Italy 113
Diclofenac 0.052–1.76 mg L1 Eﬄuents (12 municipal WWTPs) South Korea 142
230 ng L1 (median values) WWTP eﬄuents Spain (Galicia) 143
LOD ¼ 2.95 mg L1 Eﬄuents (3 WWTPs) Ireland (Dublin) 144
100–131 ng L1 STP eﬄuent Taiwan 96
53.6 ng L1 (max. conc.) Coastal receiving area
(6.6 km oﬀshore)
Taiwan 96
Mefenamic acid LOD ¼ 1.73 mg L1 Eﬄuents (3 WWTPs) Ireland (Dublin) 144
44–392 ng L1 Eﬄuents (5 STPs) South Korea 145
Ibuprofen 5 mg L1 (max. mean conc.) Eﬄuents (5 STPs) Spain 93
552–1600 ng L1 STP eﬄuent Taiwan 96
57.1 ng L1 (max. conc.) Coastal receiving area
(6.6 km oﬀshore)
Taiwan 96
<MDL – 26.6 ng L1 Treated drinking water U.S.A 101
96.9–166 624 ng L1 Landll leachate and inlet
of leachate treatment
Norway 99
120 ng L1 (max. conc.) River water U.S.A.(Washington, D.C.) 146
Beta-blockers Propranolol 1–24 ng L1 Estuary, harbour Belgium 147
3.18 ng L1 (max. conc.) Estuary Portugal 107
1.51–2.60 ng g1 Sediments of marshy areas Valencia, Spain 98
107.4  36 mg kg1 Achieved biosolids
(collected in year 2001)
from 94 WWTPS
U.S.A. 148
Atenolol 80–293 ng L1 Estuary, harbour Belgium 147
511 ng L1 (median value) WWTP eﬄuents Galicia, Spain 143
1.1–15 mg L1 Eﬄuents (5 STPs) Spain 93
261–5911 ng L1 Eﬄuents (5 STPs) South Korea 145
Blood lipid
lowering agents
Fenobrate 13.20–17.23 ng g1 Sediments of marshy areas Valencia 98
LOQ ¼ 2.5 ng g1 Sludge (3 WWTPs) Spain 122
Gembrozil 0.15–1.24 mg L1 Eﬄuent water Spain (Valencia) 149
0.08–19.4 mg L1 Eﬄuent water U.S.A. (Texas) 150
0.11–6.86 mg L1 Groundwater below Land
application site
U.S.A. (Texas) 150
Estrogens EE2 (17a-ethinylestradiol) 2 ng L1 Eﬄuents (11 STPs) UK 151
Levenogesterol 11 ng L1 Groundwater France 152
Antibiotics Ciprooxacin 1.9 mg L1 (max. conc.) Eﬄuents (5 STPs) Spain 93
Noroxacin 256  64 ng L1 Secondary eﬄuent (1 STP) China (Beijing) 153
7.23  0.22 mg kg1 Dewatered sludge (1 STP) China (Beijing) 153
Ooxacin 8.95–12.03 ng g1 Sediments of marshy areas Spain 98
528  89 ng L1 Secondary eﬄuent (1 STP) China (Beijing) 153
2.8 mg L1 (max. conc.) Eﬄuents (5 STPs) Spain 93
7.79  0.55 mg kg1 Dewatered sludge (1 STP) China (Beijing) 153
Sulfamethoxazole 13–96 ng L1 Estuary, harbour Belgium 147
9.14–53.3 ng L1 Estuary Portugal 107
0.17 mg L1 (max. conc.) Groundwater USA (California) 100
0.047–0.397 mg L1 Eﬄuents (12 municipal WWTP) South Korea 142
4.2–485 ng L1 Yangtze Estuary China 97
Lincomycin 1.06–45.7 mg L1 Eﬄuents (12 municipal WWTP) South Korea 142
1437–21 278 ng L1 Eﬄuents (5 STPs) South Korea 145
Antineoplastics Ifosfamide 4–10 647 ng L1
(median, 151 ng L1)
Hospital eﬄuent (21 hospitals) China 154
Cyclophosphamide 6–2000 ng L1
(median, 100 ng L1)
Hospital eﬄuent (21 hospitals) China 154
5-Fluorouracil 27 ng L1 (max. conc.) Hospital eﬄuent Switzerland 155
0.09–4 mg L1 (max. mean
concentration ¼ 0.8 mg L1)
Monitoring point where
hospital eﬄuent was discharged
to the sewage network
France 156
Tamoxifen 102 ng L1 (max. conc.) STP eﬄuent France 157
26.5 ng L1 (median conc.)
This journal is ª The Royal Society of Chemistry 2013 Environ. Sci.: Processes Impacts, 2013, 15, 123–144 | 129
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Table 2 (Contd. )
Category Pharmaceutical product Concentration Environmental compartment Region Reference
11 ng L1 (median conc.) River France 157
120–127 ng L1 Yangtze Estuary China 97
Psychiatric drugs Fluoxetine 8–44 ng L1 5 main rivers (Madrid) Spain 94
Noruoxetine (metabolite
of uoxetine)
41.6  25.1 mg kg1 Achieved biosolids (collected
in year 2001) from 94 WWTPS
U.S.A 148
Diazepam Upto 80 ng L1 Eﬄuents (5 STPs) Spain 93
Pipamperone 1.4–17.3 ng L1 Surface water Belgium 158
Sertraline 458  168.3 mg kg1 Achieved biosolids (collected
in year 2001) from 94 WWTPS
U.S.A 148
Carbamazepine 4–321 ng L1 Estuary, harbour, sea Belgium 147
0.37–178 ng L1 Estuary Portugal 107
1.43–5.77 ng g1 Soils of marshy areas Valencia, Spain 98
1.81–6.85 ng g1 Sediments of marshy areas Valencia, Spain 98
2–272 ng L1 River (Lopan) Ukraine 159
0.208–21 mg L1 Eﬄuents (12 municipal WWTPs) South Korea 142
3.6 mg L1 (max. conc.) Groundwater U.K. Cited in
ref. 160
0.42 mg L1 (max. conc.) Groundwater U.S.A (California) 100
Upto 6.8 ng L1 Treated drinking water U.S.A 101
161 ng L1 (max. conc.) Stormwater collection system
(discharge outfalls)
Canada 117
a Max. Conc.: Maximum Concentration; LOQ: Limit of Quantication; STP: Sewage Treatment Plant; WWTP: Waste Water Treatment Plant.
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View Article Onlineexposure to diﬀerent concentrations especially when the targets
and biochemical pathways are similar. A well-known example of
this is the ER-receptor agonist and antagonist behaviour associ-
ated with naturally occurring and synthetic hormones (e.g. ethi-
nylestradiol—the active ingredient in the oral contraceptives)
which can result in endocrine disruption.124 Sometimes non-
target organisms, e.g. algae, cyanobacteria, which have non-
related biochemical and metabolic pathways can also be eﬀected
upon exposure to pharmaceuticals.125 Organisms might show
limited toxicity in acute toxicity tests whereas higher toxicity in
chronic tests for particular chemicals.126 Mixture toxicity of PPs is
of on-going concern as is their potential eﬀects over many
generations.127 It has been observed that exposure to pharma-
ceutical products aﬀects growth and behaviour of organisms,
resulting in physical malformations, feminisation of males,
changes in photosynthetic activity and metabolic processes. To
date, very few ecotoxicity studies on pharmaceuticals have been
conducted at environmentally relevant concentrations and hence
there is inconclusive evidence to understand the true implications
of their presence in the environment. See ref. 105 for a review of
ecotoxicological studies of key pharmaceuticals. A key concern for
nanomedicines is that their dual carrier and targeting functions
may make existing PPs more bioavailable in the environment.
Early ecotoxicity studies reported toxicity eﬀects at higher
exposure concentrations and focused on growth inhibitory and
reproductive eﬀects. Recently, the shi in emphasis has been
towards assessing impacts at low concentration and assessing
the increased number of physiological biomarkers such as
studying ROS production, transcription of genes, etc. For
example, a decrease in nitrate reduction potential for ground-
water bacterial communities was observed at 5 nM concentra-
tion of exposure to sulfamethoxazole128 and changes in130 | Environ. Sci.: Processes Impacts, 2013, 15, 123–144behaviour of marine amphipods by exposure to uoxetine
(antidepressant, a selective serotonin reuptake inhibitor) at
concentrations of 10 ng L1 was reported.129 A long term study
in an experimental lake to assess the population level sustain-
ability of the fathead minnow upon exposure to low levels (5–6
ng L1) of synthetic estrogens130 has shown that there can be
collapse of a population due to feminization of the males.
Various publications have suggested the need for assessing
mixture toxicity131–133 because of the additive, cooperative and
antagonistic eﬀects of diﬀerent class and compounds of
pharmaceuticals.
Many knowledge gaps have been identied which makes the
task of conducting a plausible environment risk assessment for
pharmaceuticals challenging. These gaps in knowledge create
large uncertainties and hence inconclusive results. Further-
more, analytical challenges, e.g., non-extractable residues,
interference by other contaminates in complex mixtures of
sewage and hospital wastewater, and trace level of these
compounds complicates the matter. We summarise here the
few repeatedly mentioned knowledge gaps in the literature.
Limited knowledge exists on:
 occurrence, fate and activity of metabolites and their
transformation products in the environment, mode of action of
pharmaceuticals, metabolites and excretion rates
 long-term exposure to low levels of pharmaceuticals,
ecosystem level impact, mixture toxicity
 exposure and eﬀects data on soil organisms and marine
species, eﬀects data on ionic and polar compounds, and
 bioconcentration factors and bioaccumulation.
Intensive research in the eld of environmental occurrence,
fate and consequences of drugs and transformation products
took oﬀ in the 2000s since the rst ndings of occurrence ofThis journal is ª The Royal Society of Chemistry 2013
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View Article Onlinepharmaceuticals and their metabolites in the late 1970s in
sewage eﬄuents in the US; however, their impacts on ecosys-
tems are yet to be established with certainty. Only population
level impact attributed with certainty to pharmaceuticals is the
>95% decline in the population of the vultures in the Indian
subcontinent due to extensive diclofenac use in veterinary
medicines.134 This case study is also widely cited as an example
of unexpected routes of exposure and bioaccumulation in the
published literature on the environmental impacts of pharma-
ceuticals. Many national and international collective and cross-
sectoral eﬀorts over the past few years (e.g., ERApharm 2007,135
KNAPPE 2008 (ref. 136) in the EU, MistraPharma of Sweden)
have been able to bring the discussion to the forefront. Publicly
accessible websites such as Pharmaceuticals in the environment,
Information for Assessing Risks (http://www.chbr.noaa.gov/peiar/)
and the Swedish medicine information portal (www.fass.se)
provides information on medicines in the environment. More
recently, key gaps in knowledge to help streamline research and
eﬀorts in this eld have been identied.137 Additionally, diﬀerent
approaches for prioritisation schemes for environment risk
assessment for pharmaceuticals have been suggested, e.g. sh
plasma model, LogP ranking, hazard based rankings, QSAR
approach, and these ranking schemes have been conducted for a
substantial number of pharmaceuticals.138–140 In January this year,
the European Commission put forward the proposal to amend the
Water Framework Directives to include three pharmaceuticals in
the list of priority substances in Annex X of the Directive.141 The
positive outcome of the above-mentioned initiatives are that
regulatory steps are being taken, however, it also exemplies the
time lag between knowing, proving environmental impacts and
development or amendment of regulatory guidelines.
This table gives a very small number of the diﬀerent types of
pharmaceuticals monitored in the environment. It is meant to
provide to the reader an overview of measured concentrations
from recently published studies (2009–2012), the diﬀerent
environmental compartments where PPs have been found, and
in diﬀerent regions of the world. For detailed reviews on
occurrence, fate and ecotoxicity of pharmaceuticals and their
metabolites the reader is suggested reviews elsewhere, e.g., ref.
105, 121 and 161–163.Possible sources, fate and eﬀects of
nanomaterials (NMs)†† in the environment
The continued thrust on nanotechnology as an innovation and
economic driver‡‡164will result in development of a larger number
of new and complex materials and will inevitably result in release
of these materials in the workplace165 and subsequently in the
environment.166 The possible entry routes of NMs in the†† In this review, nanomaterials (NMs) refer to all engineered or manufactured
nanomaterials and do not cover incidental or natural nanomaterials. There is
some understanding of manufactured NM fate and behaviour and
nanomedicines, where there is little direct information, are a sub-set of NMs;
therefore we focus on engineered NMs in this section to highlight potential
nanomedicine behavior.
‡‡ See Janez Potocˇnik's, European Commissioner for Science & Research,
statement at http://cordis.europa.eu/nanotechnology/
This journal is ª The Royal Society of Chemistry 2013environment includes intentional (e.g., for remediation purposes)
or accidental releases, emissions from manufacturing facilities,
abrasion and weathering of NMs containing products. The
specic entry route into a particular environmental compartment
will depend on the life cycle of the product and disposal method
used, for example, washing of nanofunctionalised textiles will
result in release of the NMs in the sewerage system and nally
transportation to natural waters.167 To the best of the knowledge
of the authors, no actual eld level environmental monitoring of
NMs have been reported in the literature, though model envi-
ronmental concentration estimates have been calculated and
reported for selected NMs.168
As is the case of pharmaceuticals, NMs also give rise to
transformation products in various environmental conditions.
The type of transformation products that will form will depend
on the nanoscale properties of the NMs and on the conditions
of the environmental matrices, e.g., magnetic iron nano-
particles aggregate at near neutral pH due to their near neutral
zeta potential but at higher pH they are more dispersed.169 The
key transformation mechanisms can be aggregation (homo-
and hetero-aggregation), dissolution, oxidation/reduction and
adsorption.170
Under simulated situations it has been found that natural
organic matter (NOM) like humic substances171 and extracel-
lular polymeric substances172,173 inuence fate and behaviour of
NMs. Studies have shown that NOMs in the environment
inuence stability of the NM174,175 and hence bioavailability and
toxicity (reduction in toxicity shown in ref. 176, 177 and 178)
although less eﬀect of NOM on polymer coated NPs in some
cases.179 It has also been demonstrated that silver NPs in
organic matter rich soil become more bioavailable aer
aging.180 In addition to NOM, physico-chemical properties of
the aqueous environmental compartment like pH, ionic
strength, salinity, mineral content/hardness, etc. have also been
shown to inuence fate, behaviour and toxicity. For instance, it
was shown that E. coli survived at pH 10 even at concentrations
of iron oxide NPs (beq of 109 mg L
1 of FeOx), however, S. cer-
evisiae (an eukaryote) had survival rates of less than 10%.181
Hardness of water, at near neutral pH, can result in formation
of aggregates and biouptake by lter feeders182 or settling down
and available to pelagic organisms or earthworms. High total
organic carbon (TOC) and low ionic strength, conditions in
freshwaters, can stabilise NMs and make it persistent and be
available for lter feeders, sh and algae and low TOC and high
ionic strength such as in sea water can aid in their rapid
aggregation and settling.183 Please see ref. 184–187 for further
studies on possible fate, behaviour and eﬀects of engineered
nanomaterials in the environment.
The key factors inuencing toxicity are composition, size,
surface properties (both for the NM and the transformed
products), sensitivity of the species and presence of other
contaminants. For example, cationic branched polymer [poly-
ethyleneimine (PEI)] coated AgNPs (10 nm) was shown to have
increased toxicity to a Gram +ve bacterium, bacillus sp. when
compared to citrate and PVP coated AgNPs.188 Similarly, posi-
tively charged AuNPs of 2 nm size was reported to lyse Bacillus
subtilis, but observed to have no eﬀect on E. coli, a Gram veEnviron. Sci.: Processes Impacts, 2013, 15, 123–144 | 131
Fig. 1 A conceptual schematic showing likely sources and transport of nanomedicine into the environment. Nanomedicines and transformed products may be
released into the water through the excretory routes, washing oﬀ from skin, frommanufacturing facilities, spillages and disposal of product. They can be released in the
atmosphere from nasal inhalers. Incineration of composite medical products and abrasion and weathering in landﬁlls may lead to release into the atmosphere.
§§ Bile formation in the liver helps to bio-transform the drug and helps in drug
metabolism. Excretion is primarily in the form of faeces. Other routes of drug
excretion are via saliva, breast milk, intestinal exosorption (see ref. 201).
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View Article Onlinebacterium.189 Bioaccumulation and trophic transfer of NMs can
also happen.190,191 Many investigators have shown biolms to be
an eﬀective sink for NMs190,192,193 and aquatic organisms like
lter feeders to uptake and biotransform suspended and
dispersed NMs present in the aquatic matrix.194,195 Furthermore,
exposure of organisms to NMs would be dependent on the
presence of other environmental contaminants, mode of action
of the chemical and the diﬀerences in physiology of species.
Phenanthrene adsorbed on n-C60 was shown to be more
bioavailable to algae and daphnids, but was found to be more
toxic to algae196 and the investigators suggested the diﬀerence in
physiology to be the reason for this observation. Whereas, n-C60
fullerenes was shown to sequester the synthetic hormone, 17-a
ethinylestradiol (EE2) hence reducing its bioavailability.197
Similarly, it was demonstrated that mixed iron oxide NMs in
organic matter rich environment (humic acid >20 mg L1), low
salinity (tap water and deionised water), and in a pH range of 5–
7 could adsorb the antibiotic chlorotetracycline.198 Interactions
between hydrophobic NMs and pharmaceutical products can
sequester PPs from the environment hence reduce or increase
their bioavailability in a given time frame.
Possible sources, fate and eﬀects in the environment of
nanomedicines
There is insuﬃcient knowledge regarding possible amounts
and entry routes of nanomedicine products in the environment,
however it should not deter one frommaking estimates of likely
routes of entry, based on knowledge of environmental release
and transport of pharmaceuticals. Fig. 1 is a conceptual model132 | Environ. Sci.: Processes Impacts, 2013, 15, 123–144of likely release and exposure pathways of nanomedicine and a
key research issue is to quantify the concentrations and uxes
within this conceptual model. There are diﬀerent entry routes
for various medical NMs in the environment. In case of thera-
peutic applications, the obvious route is the renal and the
hepatobiliary§§ routes of excretion to domestic sewage and
then subsequently to waste water treatment plants and to
receiving water bodies and land (with the caveat mentioned
earlier that a large percentage of waste water even in the EU goes
untreated). Other possible routes are likely to be NM release
into the air from inhalers, disposal of unused medicine at
hospitals, R&D labs, and clinical research facilities by casual
and ill trained staﬀ, NM release during manufacturing, trans-
port and accidental spills, and from the incinerators. Due to
high specic surface areas NMs might get adsorbed on to waste
solids of the combustion chamber in an incinerator or be
present in the oﬀ-gas.199 However, complete removal of NPs
below 100 nm from the oﬀ gas of the incinerator might not
happen, even aer state-of-the art eﬄuent gas treatment
processes.200
In case of medical devices, improper disposal of the devices
at end of their life, especially disposable of in vitro diagnostic
products is likely to release NMs into the environment.
Although we know quantitatively very little at the moment, a
priori it might be expected that certain pathways are likely to beThis journal is ª The Royal Society of Chemistry 2013
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View Article Onlineof major importance, including: (1) waste water and stormwater
to waste water and sludge and then to freshwater and soil; (2)
treated ue gas from incineration to atmosphere and then to
water and soil and (3) landll to groundwater and soil and then
to surface water.Biotransformation and excretion
Ingested and injected PPs are amenable to biotransformation in
the body due to the action of various enzymes and are excreted
primarily with urine and/or faeces.201 Studies have been per-
formed to nd out the clearance mechanisms of NMs with
prospective use in medicine. Biodistribution studies with gold
nanoparticles have been conducted by diﬀerent investigators
and it has been found that the clearance pathway is dependent
on size, surface coating and charge of the particle. Lipka et al.202
showed that 10 kDa PEG coated 5 nm AuNPs followed the
hepato-biliary clearance route, whereas another study203 showed
uncoated 20 nm AuNPs to be primarily recovered in the urine. A
recent study showed that hepato-biliary clearance was inversely
related to negatively charged AuNPs of diﬀerent sizes (1.4, 2.8, 5,
18, 80, 200 nm). The investigators concluded that the small
sized negatively charged AuNPs were excreted out via the hep-
ato-biliary excretion pathway because of “dynamic protein
binding and exchange which are major mechanisms deter-
mining the AuNP accumulation in the various organs and
tissues.”.204 By extension, there might be diﬀerences in bio-
distribution prole of encapsulated and free drug. A study
showed that urinary excretion of the unaltered drug when
encapsulated in poly-epsilon-caprolactone (a widely researched
polymer for medical applications) nanocarriers increased by
15% in comparison to the administration of non-encapsu-
lated drug,205 hence would result in more discharge to the
environment unless dosages are altered. Biological fate of a
model PEG–protein was studied and it was found that 46.5% of
PEG of the administered dose was excreted out of the urine over
a period of few days. The same study also reported that intact
PEGylated model protein was excreted out in the rst few days
post administration of the model protein.206
In many cases, nanoformulations help to reduce systemic
toxicities especially for anticancer drugs. For example, nab-
paclitaxel, a nanomedicine in the market, is a formulation of
paclitaxel (empirical formula: C47H51NO14, a plant alkaloid)
bound to albumin nanoparticles withmean particle size 130 nm
has been shown to have better therapeutic eﬃcacy than
conventional paclitaxel (Taxol) for breast cancer. The dosage
of this new formulation is 260 mg m2 of body surface area
every 3 weeks (Taxol's prescribed dosage ranges from 135 mg
m2 to 175 mg m2 of body surface area every 3 weeks),207,208
showing the possibility of higher doses that can be achieved
through nanoformulation. Traditional chemotherapeutics are
highly hydrophobic drugs, and hence are generally assumed to be
adsorbed on to the sludge of STP123 and thenmainly incinerated or
spread on agricultural soils (Switzerland and UK, respectively).
The possibility of administering increased dosages and changed
excretion proles due to the new nanoformulations will likely
increase the environmental concentration of these highly cytotoxicThis journal is ª The Royal Society of Chemistry 2013pharmaceutical products. The above examples indicate the likely
problem areas; however, the authors acknowledge the fact that
more targeted medicines, customised for small populations (per-
sonalised medicines) and possibility of reduction in premed-
ication amounts might result in a more favourable benet-risk
balance when all aspects are taken into consideration.Fate and behaviour
Polymer coating on NMs will aﬀect the fate and behaviour of
NMs in waste water treatment plants. Tween 20 coated silica
oxide nanoparticles (56 nm) were shown to remain in the
sludge, whereas uncoated silica oxide NP did not occulate and
remained in the eﬄuent.209 Biolms can act as potential ‘sinks’
for NMs either in the secondary treatment stage of a sewage
treatment plants or in fresh water ecosystems. Sometimes, the
polyethylene glycol (PEG) coating on NM can integrate itself
with the protein component of the biolm and change the
roughness co-eﬃcient of the biolm but shielding the toxic
eﬀects of the core particle.192 The size can also have an inuence
of changing the morphological properties of a biolm. Stojak
et al. reported an increase in roughness coeﬃcient and signif-
icant decrease in plankton biomass in a L. pneumophila mature
biolm aer 2 days of exposure to citrate capped of Au nano-
particles of sizes 4 and 18 nm.193 However, no change was
observed in the biolm exposed to 50 nm gold NPs. Further-
more, it was observed that the 4 nm and 18 nm AuNPs got
adsorbed onto the exopolysaccharides of bacterial cell wall and
also got entrapped in the bacterial cell.193 Polymers may be
utilised as carbon/energy sources. It was recently demonstrated
that PEG coated NM could be degraded by bacteria from an
urban stream. However, the degradation rate and aggregation
depended on the available chain end groups of the two diﬀerent
types of polymer coated NMs studied.210 Polymer (poly ethylene
glycol-b-3-caprolactone) coated nanoparticles were found to
irreversibly adsorb onto cellulosic surface and the adsorption
mechanism was found to be size dependant. The investigators
hypothesised that adsorption could be due to interdigitation
and entanglement of the nanoparticles with the D-glucose
chains of cellulose.211Biouptake and eﬀects
Monodispersed, stable and targeted nanomaterials are impor-
tant for medical applications, e.g., monodispersed iron oxide
nanoparticles7,212 to fully exploit their novel properties, increase
shelf life and to inuence physiological responses with
increased eﬀectiveness. These same design requirements may
dictate the fate and risk of the nanomaterial in the environment
by not only arresting growth and reproduction, but also inter-
fering with metabolic processes and hence in turn impacting
key ecosystem services. However, to a certain extent organisms
might be able to tolerate the exposure of nanomedicines
although this is poorly quantied.
Nanoparticles are coated with organic polymer coatings
to escape the mononuclear phagocytic system in the body
(‘stealth’ properties) or to especially target cells. There areEnviron. Sci.: Processes Impacts, 2013, 15, 123–144 | 133
Table 3 Select ecological studies of toxicity eﬀects, uptake and bioaccumulation for NMs and nanocarriers with likely use in nanomedicine
The ‘nano’ component
in nanomedicine
Short description of select ecological studies of toxicity eﬀects, uptake and bioaccumulation for NMs
and nanocarriers with likely use in nanomedicine References
Polyethyleneimine (PEI)
polymer
For tadpole larva, Xenopus laevis, both PEI and PEI:DNA (polyplex) showed teratogenic eﬀects at
concentrations 0.1 mg L1. PEI also showed higher toxicity for the algae Pseudokirchneriella subcapitata;
EC10 ¼ 40.8 mg L1. The polyplex was found to be less toxic to the algae than the free polymer
213
Dendrimers Commercially available amine terminated G4 dendrimer showed sublethal toxicity in zebrash embryos
at 0.2 mM concentrations, whereas COOH terminated G3.5 dendrimers did not exhibit toxicity even at
concentrations of 200 mM. Dose and time dependant mortality was observed for amine terminated G4
dendrimer, 100% mortality at dose 20 mM in 24 h post fertilisation
214
Green algae Chlamydomonas reinhardtii exposed to commercially available amine terminated G2 (2.6
nm), G4 (4.4 nm), G5 (5.7 nm) poly(amidoamine) PAMAM dendrimers showed decreased cell viability at
2.5 mg L1 (median IC 50 as per dendrimers generation: G2, G4, G5, – 2 mg L
1, 3 mg L1, 5 mg L1). O2
evolution from photosynthesis signicantly increased at concentrations 1 mg L1 and 2.5 mg L1 for G2
and G4 dendrimer (increase in PSII reaction centres and e transport). Exposure concentrations: 0.3, 1,
2.5 and 10 mg L1. Exposure duration: 72 h
215
Commercially available G4 cationic PAMAM dendrimers with diaminobutane core at 15 nM, 25 nM and
35 nM concentrations resulted in a linear increase in ROS level and photosynthetic oxygen level in the
algae, C. reinhardtii. Also, most of the transcripts encoding proteins involved in photosynthesis and
antioxidant genes were down regulated except for the gene which encodes light-harvesting polypeptide
for PSII (this was upregulated). Measured size range: 90 nm in MQ water. Exposure duration: 6, 24 h
216
A dose-eﬀect study of amine terminated G4 and G1 PAMAM dendrimers with ethylenediamine core was
conducted for P. subcapitata. The amine-terminated G4 dendrimer was found to be comparatively more
toxic than the amine terminated G1 dendrimer. The negatively charged hydroxyl terminated G4
dendrimer had least toxicity
217
SPIONS and USPIOs
(<25 nm core)
Pumpkin plants (Cucurbita maxima), when grown hydroponically could translocate and accumulate
coated magnetite (Fe3O4) nanoparticles (20 nm size). Strongmagnetisation signals were observed in the
leaves. Exposure concentration: 0.5 g L1; exposure period: 20 days. Also, when pumpkin plants were
grown in soil, no magnetisation signal was noticed in the plants but when grown in sand, the pumpkin
plants accumulated the iron nanoparticles. Lima bean plants didn't accumulate Fe3O4 nanoparticles
218
Higher activity of the oxidative stress enzyme catalase was reported for PVP coated magnetite (Fe3O4)
nanoparticles (25 nm) and bulk iron oxide NPs in the shoots of both rye grass and pumpkin plants and
roots of rye grass plants. Exposure concentrations: 30 mg L1, 100 mg L1 of nano-(Fe3O4) and 30 mg
L1 and 100mg L1 of Fe3O4 bulk. Exposure duration was 18 days. Lipid peroxidation was also reported.
No magnetism was observed in the shoots of both the plants, indicating, that the iron NPs were not
translocated. The oxidative stress enzyme superoxide dismutase activity was found to be higher in the
roots of both the plants for iron bulk and nanoparticles at 30 mg L1 concentration
219
In the presence of sublethal concentrations of As(V) (to rule out the probability that environmental
arsenic is causing the toxicity), commercial nano-Fe2O3 (20–40 nm) was shown to have increased toxic
eﬀect on C. Dubia. It was established nano-Fe2O3 and As(V) caused the toxic eﬀect in a synergistic mode
(nano-Fe2O3 alone didn’t exhibit mortality under the concentrations used in the study). It was found
that 48 hour mortality was dose dependant but 24 h mortality was not. At 20 mg L1 of nano-Fe2O3, the
48 hour mortality increased from 30% to 70% and then the mortality rate remained nearly constant for
higher exposure doses. Depuridation (upto 75%) occurred aer an hour for solutions having algal feed.
It was observed that maximum bioaccumulation occurred at neutral pH. Exposure concentration: 1, 5,
10, 20, 50 mg L1
220
Gold nanoparticles
(diﬀerent sizes for
diﬀerent medical
applications; general
size range 5–30 nm)
Decrease in colony forming units of soil microbial community aer 15 days of exposure to commercial
available AuNPs. Higher shoot/root ratio of lettuce exposed to AuNPs observed indicating that AuNPs
acted as a growth promoter. Concentration: 0.013% w/w in soil. Exposure time in soil: 15 days
221
Size selective uptake of citrate capped AuNP by tobacco plants. 3.5 nm AuNPs were found in the leaves of
the plants and the 18 nm AuNPs remained agglomerated/aggregated at the root surface. Necrotic lesions
in leaves and death of plants occurred aer 30 days of exposure. Concentration: 3.5 nm – 48 ppm; 18 nm
– 76 ppm. Exposure duration: 3 to 30 days
222
Mean ‘Au’ concentrations in tobacco plants were found to be between 2.2 mg kg1 to 53.5 mg kg1 when
hydroponically exposed to tannate and citrate coated 10, 30, 50 nm of AuNPs. In contrast, wheat plants
when exposed to the same exposure concentrations didn't show any uptake. However, it was found that
aggregation of AuNPs occurred more in the wheat than the tobacco plant suspensions. Exposure
concentration: 30 mg L1. Exposure time: 7 days for tobacco and 3 days for wheat
223
No obvious toxic eﬀects of cucumber and lettuce seeds could be seen when exposed to AuNPs of mean
size 10 nm at 2.4  1012 NP mL1 concentration
224
Polyvinyl alcohol (PVA) capped Au NPs [size range: 15–35 nm (spherical shape)]. Exposure
concentrations: 10, 25, 50, 75, and 100 mg mL1 were used to study their impact on embryos of zebra
sh. The embryos developed normally (similar to the controls) – eyes, tail, brain and otoliths. No change
in blood ow or cardiovascular development was observed. Detectable AuNP accumulation was
observed in the body of treated embryos (25 and 50 mg mL1)
225
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Table 3 (Contd. )
The ‘nano’ component
in nanomedicine
Short description of select ecological studies of toxicity eﬀects, uptake and bioaccumulation for NMs
and nanocarriers with likely use in nanomedicine References
Zebrash exposed to citrate stabilised gold nanoparticles (12 and 50) nm through feed. Daily dose 90 ng
and 106 ng for 12 and 50 nm Au NPs. Exposure duration 36 days. Daily dose: 36 and 42 ng for 12 and 50
nm AuNPs respectively. Exposure duration: 60 days. AuNPs were found in brain, liver and skeletal
muscles with highest concentration of 12 nm AuNPs in the brain. Up-regulation of DNA repair genes,
increase in mutation and mitochondrial impairment was observed and was more for the 60 days
exposure duration
226
(1) Feed containing citrate capped 15 nm AuNPs fed to D. melanogaster. Max. dose: 12 mg per g per day.
Life span and fertility was negatively aﬀected. Reproductive performance decreased with exposure to
increasing AuNP doses (from 1.9 pmol L1 to 380 pmol L1) during embryonic and larval development.
Overexpression of heat shock protein occurred reective of ER stress and DNA fragmentation in the
gastrointestinal tissue was observed
227
(2) Feed containing citrate capped 15 nm AuNPs fed to D. melanogaster. Max. dose: 3 mg per g per day.
Mutagenic eﬀects were observed and aberrant phenotypes were observed in subsequent (F1 and F2)
generations
228
Oxidative stress observed in Mytilus edulis, a marine bivalve mollusc, when exposed to 750 ppb AuNPs
(5.3 nm size), for 24 h. The study also showed that larger size Au-NPs resulted in lower oxidative stress in
the animal. It was found that the AuNPs accumulated mainly in the digestive gland
229
Filter-feeding bivalve Corbicula uminea (1–2 years of age) exposed to Bovine Serum Albumin (BSA)
coated AuNPs of sizes 7.8 nm, 15 and 46 nm. Exposure concentration: 2 mg L1. Total exposure time:
180 h
194
 Eﬃciency of removal of AuNPs from solution due to ltration by the bivalves was size dependant and
removal eﬃciency increased with particle size
When the bivalves were exposed to varying concentrations (2 mg L1, 4 g L1 and 8 mg L1) of 46 nm
size BSA–Au NPs, it showed that removal eﬃciencies from solution to be positively related with
concentration of BSA–AuNPs solution
 The AuNPs were evidenced in the digestive gland and regions of the digestive tract and mass
concentration inside the body of the clam was more for the 15 nm of BSA–AuNP exposed bivalves
 The bivalves exposed to 7.8 nm AuNPs particles, didn't eﬃciently excrete it during the experimental
period and it was found that AuNPs concentrations remained elevated in these bivalves. 15 and 46 nm
BSA–AuNP exposed bivalves excreted out the AuNPs more eﬃciently
Evaluation of toxigenomic response of Caenorhabditis elegans (soil nematode) exposed to 4 nm citrate
capped AuNPs (LC10¼ 5.9 mg L1 at 24 h and same concentration used for the genetic response analysis
to AuNPs). Observations reported are as follows
230
 Upregulation of genes related to clathrin-mediated endocytotic pathway
 Upregulation of Ca+ signalling and amyloid processing pathway (protein unfolding and denaturation)
 Upregulation of heat shock protein genes (reective of ER stress)
Silicon oxide NPs Commercially available silica NPs (50% were below size 100 nm, 40% were between 100 and 200 nm) at
concentrations of 0.825 mgmL1 was shown to aﬀect the endoplasmic reticulum function leading to ER
stress response, in a sh broblasts cell line
231
Commercially available silica NPs of size 10–20 nm diameter were found to decrease growth rate of S.
obliquus (a fresh water green algae) as a function of concentration (50, 100, 150mg L1) and time (48, 72,
96 h).
232
Contents of chlorophyll-a and b decreased by 86.4% and 94.8% as compared to the control group, but
the amount of carotenoids didn't decrease. Exposure duration: 96 h of exposure at 50 mg mL1
SiO2 NPs (commercially available) of 12.5 and 27 nm shown to be toxic to P. subcapitata (green algae)
EC20 was found to be 20 5mg L1 and 28.8 3.2 mg L1 for 12.5 nm and 27 nm. Adsorption to the cell
wall was seen but no cellular uptake was observed by the investigators. Exposure duration: 72 h
233
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View Article Onlinelimited numbers of ecotoxicity studies which have been con-
ducted with polymers used in medical applications, of the few
that we are aware of, most of the studies have been done on
dendrimers.
Dendrimer toxicity has been shown to increase with increase
in the generation of cationic dendrimers for various model
organisms (D. magna, V. scheri, P. subcapitata, T. platyurus).
Table 3 gives a summary of selected ecotoxicity studies which
can be linked with NMs used in medical applications. The
environmental sources, fate and eﬀects of AgNPs have been
widely reported in the scientic literature and therefore thisThis journal is ª The Royal Society of Chemistry 2013table does not cover ecotoxicity studies of AgNPs. Readers are
referred elsewhere for a review on fate and eﬀects of AgNPs in
the environment.184Regulatory framework for medicines and
medical devices in the EU
Regulations for pharmaceuticals for human use
Extensive studies for assessing toxicity are conducted aer
identication of a promising new entity that has a therapeutic
potential. A battery of tests and assays are performed toEnviron. Sci.: Processes Impacts, 2013, 15, 123–144 | 135
Fig. 2 General stages of nanomedicine development and the key points of interaction between regulatory agencies and nanomedicine developers. Good Laboratory
Practices, Good Manufacturing Practices, Good Clinical Practices are the quality and ethical guidelines followed by pharmaceutical companies and researchers and
monitored by regulators. Rapid advancement in technology and science and need for innovation to be an economic driver, regulatory agencies are present in earlier
stages of product development.
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View Article Onlineunderstand whether there are risks for human carcinogenicity,
genotoxicity, reproductive and development toxicity, immuno-
toxicity, etc.). Pharmacodynamics and pharmacokinetics
studies are conducted in small animal models to assess the
distribution of the drug, the mode of action and physiological
eﬀects, metabolism and excretion. Data from these studies is
required to be submitted to the relevant medical regulatory
agency before enrolling human subjects to establish the safety
and eﬃcacy (Phase I to Phase III clinical trial) of the new drug.
The preclinical and the clinical trial data form the basis of the
marketing authorisation application (MAA) in the EU and
member states. Applications for therapeutics for cancer,
neurodegenerative diseases, HIV/AIDS and immune dysfunc-
tions, and viral diseases are submitted to the centralised
medical regulatory agency in the EU, the European Medicines
Agency. A few other therapeutics which go through the cen-
tralised procedure include oﬃcially designated ‘orphan’{{
medicines, biotechnology based therapeutics, tissue engi-
neering products. Marketing surveillance (‘pharmacovigilance’)
of the medicine post authorisation are other regulatory steps{{ To qualify for orphan designation, a medicine must meet one of these criteria
(as dened by the EMA, ref. 234): (1) it is intended for the diagnosis, prevention
or treatment of a life-threatening or chronically debilitating condition aﬀecting
no more than 5 in 10 000 people in the EU at the time of submission of the
designation application; (2) it is intended for the diagnosis, prevention or
treatment of a life-threatening, seriously debilitating or serious and chronic
condition and without incentives it is unlikely that the revenue aer marketing
of the medicinal product would cover the investment in its development.
136 | Environ. Sci.: Processes Impacts, 2013, 15, 123–144which should help to monitor the therapeutic agent's safety.
Fig. 2 is a simplied depiction of the medicine innovation
pathway, key checkpoints with regard to regulatory agency
involvement and the underlying guidelines for ethics and safety
during innovation. The decision for approving a medicine is
based on the careful evaluation of the benet-risk assessment of
a particular therapeutic for the target group of patients.Medical devices legislation
The regulatory context with regard tomedical devices in the EU is
substantially diﬀerent to that of medicines for human use.
Medical device and medicine regulatory pathway have distinct
and clearly demarcated regulatory process. The medical device
directives are implemented at EU member state level with no
overarching body at the EU level. There are three diﬀerent
regulations to capture all the diﬀerent types of devices used in
the medical industry – the Medical Devices Directive, Active
Implantable Medical Device Directive, and In Vitro Diagnostic
Medical Device Directive. Combination products i.e. integration
of a medical device and medicine, spurred by nanotechnology,
has blurred the distinction between the two distinct regulatory
pathways and need for revisions in the current legal framework
has been voiced in the public consultation process, a part of the
undergoing process of revision (2008-onwards) of the medical
devices directives. Also, few member state regulators (e.g. UK,
Sweden) have taken required steps towards addressing the issue.
Medical devices are classied according to their perceived
level of risk – Class I representing the lowest level of expected/This journal is ª The Royal Society of Chemistry 2013
Fig. 3 Key requirements in the tiered environment risk assessment process for medicines for human use. For anti-microbials, if the PNEC:PECsw is less than 0.1, need for
extended environmental fate and eﬀect studies becomes mandatory which includes soil and sediment compartments and terrestrial organisms. PNEC: Predicted No
Eﬀect Concentration; PEC: Predicted Environmental Concentration; Koc: adsorption co-eﬃcient; Kow: octanol–water co-eﬃcient; PECsw: PEC surface water; PECgw: PEC
ground water.
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View Article Onlineperceived risk and Class III representing the highest level of
risk. The degree of risk assigned then determines the level and
type of evidence required for award of CE (Conformite´ Euro-
pe´enne) mark. Clinical data is required for awarding a CE mark
for Class III medical devices but are not mandatory; literature
analysis showing clinical investigations and experience related
to similar devices and appropriate justication can be used for
submission of application for approval.235 Tests to identify
human toxicological risks from materials used in medical
device components, (e.g. polymers) need to be performed.
However, no environmental risk assessment of medical devices
is required. Unfortunately, the medical devices directives do not
cover the entire life cycle of the product and their disposal in the
EU was according to the WEEE Directive (Waste Electronic and
Electrical Equipment Directive 2002/96/EC) which did not
mandate recycling and recovery percentages for medical devices
giving rise to the concern that similar environmental and
occupational health problems as electronic waste 236 may occur
for the use of cost-eﬀective mass produced nano-enabled in vitro
diagnostic tools. However, the recently revised WEEE Directive
has mandated recovery and recycling targets for certain medical
devices.237Current regulatory context (human medicines) related to
environmental safeguard
The European Medicines Agency's Guideline on Environmental
Risk Assessment (ERA) of pharmaceuticals102 follows a tieredThis journal is ª The Royal Society of Chemistry 2013assessment approach: Phase I and Phase II (Tier A and Tier B).
Fig. 3 gives a concise schematic explanation of the approach. An
ERA needs to be provided with every new marketing author-
isation application (MAA) for a pharmaceutical; however,
granting of market authorisation is independent of environ-
ment impact.
There are two initial pre-screening steps – (a) if the predicted
environment concentration of the pharmaceutical exceeds the
threshold value of 0.01 mg L1 (0.01 ppb), then it triggers the
need for conducting few acute ecotoxicity tests on regulatory
species to calculate the Predicted No Eﬀect Concentration
(PNEC) (b) if the octanol–water partition co-eﬃcient (log Kow) is
greater than 4.5, persistence, bioaccumulation and toxicity
(PBT) assessment tests need to be conducted by following
ECHA's guidance on chemical safety assessment. Firstly, the
questions arise, how is the PEC calculated for nanomedicines?
Apart from concerns which are similar to all NMs, should it to
be based on the drug, the nanocarrier or on the nanocarrier–
drug conjugate? How would the PEC be derived for more
complex nanomedicines? As with all NMs, nanomedicines may
present unique concerns and the applicability of such ERAs
have not been fully demonstrated.
Secondly, it is well established that log Kow has deciencies
as a surrogate for determining mobility and partitioning of PPs
or for application to NMs.238 For example, the antidepressant
carbamazepine was found in sh tissues from eﬄuent domi-
nated streams though the drug has a log Kow of 2.67. Similarly,
ciprooxacin, an antibiotic, sorbs well onto active sludge orEnviron. Sci.: Processes Impacts, 2013, 15, 123–144 | 137
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View Article Onlinesediments,153,239 despite a log Kow of1.74 (cited in ref. 240) and
it was found to be persistent.241 It has been widely debated that
log Kow for acidic and basic drugs is misleading, because the
coeﬃcient is dependent on solution pH, ionic strength, NOM
and other factors. In the case of NMs, the inadequacy of the test
protocol to determine log Kow has been discussed.238 A study
performed on diﬀerent generations of dendrimers showed that
for dendrimers with terminal NH2 group, the log Kow of the
polymer was negative for G1–G5 PAMAM dendrimers and G6–
NH2 and G8–NH2 dendrimers partitioned at the octanol–water
interface.242 The negative log Kow indicates that under the
current ERA guidelines, there will not be any need to conduct a
TIER 1 risk assessment. Similarly, PEG has negative log Kow and
it doesn't change much with the chain length, furthermore, it is
not easily biodegradable.
Although the action limit 0.01 mg L1 is very low, it is based
on acute rather than chronic toxicity tests and it has been widely
discussed both for pharmaceuticals and nanomaterials, that
chronic and sub-lethal toxicity end points are important to
assess the environmental risks of the product and that the link
between chronic and acute toxicity is not well established for
NMs. Furthermore, the test protocols suggested in the ERA
Guidelines for human pharmaceuticals for conducting the
physical–chemical fate and eﬀects studies is based on OECD
test guidelines for chemicals. The recommended study types
include adsorption–desorption using a batch equilibrium
method, a ready biodegradability test, aerobic and anaerobic
transformation in aquatic test, algae growth inhibition,
daphnia reproduction test, etc. The drawbacks and the need for
adaptability of the current OECD tests and protocols, originally
meant for chemicals, with respect to NMs have been discussed
and reviewed.243,244 Key issues are the inuence of the test
medium conditions on the NMs,245–247 the need to include
benthic and lter feeding organisms as test species, the
necessity of investigating chronic eﬀects and nding novel
toxicity end points, the need for extensive in situ physico-
chemical characterisation, the limited applicability of the
persistence and bioaccumulation tests. The applicability of
testing to nanomedicines will include the same issues and
perhaps other specic ones including role of the nanocarrier in
increased uptake.Knowledge gaps and uncertainties and
conclusion
Despite much progress in recent years, knowledge and data gap
exists for pharmaceuticals, including their metabolic products
and excretion rate, and their environmental fate and behaviour,
removal eﬃciencies in sewage treatment plants, chronic toxicity
data and bioaccumulation.136 In nanotoxicology and nano-
ecotoxicology, the key gaps include environmental concentra-
tions, environmental fate and behaviour, dynamic changes in
physical and chemical properties both in vitro and in vivo,
applicability of exposure assays, dose metrics for exposure
assessment, biouptake and toxicity mechanisms and chronic/
acute toxicity relationships.185–187,243 In nanomedicine, all these
gaps in knowledge and data apply, along with others such138 | Environ. Sci.: Processes Impacts, 2013, 15, 123–144potential discharges to the environment and medium term
growth in applications. Given the signicant potential benets
of nanomedicine such as potential for dose reduction, it is
imperative to further understand any potential environmental
risks to allow the long term safety, sustainability and develop-
ment of the industry. However, further understanding of the
impacts of nanomedicine in the environment can be provided
by use of data from the pharmaceuticals, environmental and
nanoscience elds. In addition, sophisticated models and
techniques are available which can be applied and adapted to
understanding the environmental implications of nano-
medicine. Although caution needs to be exercised as there will
be discipline-dependent diﬀerences, such methods, data and
models provide a solid platform for future more specic studies
which are urgently needed.Acknowledgements
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